Skip to main content
Erschienen in: Tumor Biology 2/2012

01.04.2012 | SI: Epigenetics in Cancer

AKT signaling pathway activated by HIN-1 methylation in non-small cell lung cancer

verfasst von: Yuanzi Yu, Dongtao Yin, Mohammad O. Hoque, Baoping Cao, Yan Jia, Yunsheng Yang, Mingzhou Guo

Erschienen in: Tumor Biology | Ausgabe 2/2012

Einloggen, um Zugang zu erhalten

Abstract

The purpose of this study is to determine the epigenetic changes and function of High in Normal-1 (HIN-1) in non-small cell lung cancer (NSCLC). HIN-1 expression was examined by semiquantitative RT-PCR before and after 5-aza-2′-deoxycytidine (5-aza) treatment in NSCLC cell lines. Promoter methylation status of HIN-1 was tested by methylation-specific PCR (MSP). Effect of forced expression of HIN-1 on different key molecules of AKT signaling pathway was tested by Western Blot analysis in H157 and H23 cell lines. Promoter methylations are inversely correlated with expression of HIN-1 in eight (H23, H157, 95D, H1299, H358, H1752, H460, A549) of ten NSCLC cell lines and re-expression was observed by 5-aza treatment. We then tested promoter methylation of HIN-1 in primary NSCLC tissues. Methylation was detected in 73 out of 152 (48%) NSCLC cases. Forced expression of HIN-1in NSCLC cell lines inhibited colony formation and induce apoptosis. Furthermore, overexpression of HIN-1 reduces the expression of phosphorated-AKT (p-AKT), c-myc, Bcl-2 and cyclinD1 while Bax was increased. Our data suggest that HIN-1 is a potential tumor suppressor gene in NSCLC, silenced by promoter hypermethylation and negatively regulate AKT signaling pathway.
Literatur
1.
Zurück zum Zitat Jemal A, Siegel R, Xu J, Ward E. Cancer Statistics, 2010. CA Cancer J Clin. 2010;60:277–300.PubMedCrossRef Jemal A, Siegel R, Xu J, Ward E. Cancer Statistics, 2010. CA Cancer J Clin. 2010;60:277–300.PubMedCrossRef
2.
Zurück zum Zitat Zhou W, Christiani DC. East meets west: ethnic differences in epidemiology and clinical behaviors of lung cancer between East Asians and Caucasians. Chin J Cancer. 2011;30:287–91.PubMedCrossRef Zhou W, Christiani DC. East meets west: ethnic differences in epidemiology and clinical behaviors of lung cancer between East Asians and Caucasians. Chin J Cancer. 2011;30:287–91.PubMedCrossRef
3.
Zurück zum Zitat Brock MV, Hooker CM, Ota-Machida E, Han Y, Guo M, Ames S, Glöckner S, Piantadosi S, Gabrielson E, Pridham G, Pelosky K, Belinsky SA, Yang SC, Baylin SB, Herman JG. DNA methylation markers and early recurrence in stage I lung cancer. N Engl J Med. 2008;358:1118–28.PubMedCrossRef Brock MV, Hooker CM, Ota-Machida E, Han Y, Guo M, Ames S, Glöckner S, Piantadosi S, Gabrielson E, Pridham G, Pelosky K, Belinsky SA, Yang SC, Baylin SB, Herman JG. DNA methylation markers and early recurrence in stage I lung cancer. N Engl J Med. 2008;358:1118–28.PubMedCrossRef
4.
Zurück zum Zitat Guo M, Akiyama Y, House MG, Hooker CM, Heath E, Gabrielson E, Yang SC, Han Y, Baylin SB, Herman JG, Brock MV. Hypermethylation of the GATA genes in lung cancer. Clin Cancer Res. 2004;10:7917–24.PubMedCrossRef Guo M, Akiyama Y, House MG, Hooker CM, Heath E, Gabrielson E, Yang SC, Han Y, Baylin SB, Herman JG, Brock MV. Hypermethylation of the GATA genes in lung cancer. Clin Cancer Res. 2004;10:7917–24.PubMedCrossRef
5.
Zurück zum Zitat Guo M, House MG, Hooker C, Han Y, Heath E, Gabrielson E, Yang SC, Baylin SB, Herman JG, Brock MV. Promoter hypermethylation of resected bronchial margins: a field defect of changes? Clin Cancer Res. 2004;10:5131–6.PubMedCrossRef Guo M, House MG, Hooker C, Han Y, Heath E, Gabrielson E, Yang SC, Baylin SB, Herman JG, Brock MV. Promoter hypermethylation of resected bronchial margins: a field defect of changes? Clin Cancer Res. 2004;10:5131–6.PubMedCrossRef
6.
Zurück zum Zitat Herman JG. Epigenetics in lung cancer: focus on progression and early lesions. Chest. 2004;125:119S–22S.PubMedCrossRef Herman JG. Epigenetics in lung cancer: focus on progression and early lesions. Chest. 2004;125:119S–22S.PubMedCrossRef
7.
Zurück zum Zitat Klug J, Beier HM, Bernard A, Chilton BS, Fleming TP, Lehrer RI, Miele L, Pattabiraman N, Singh G. Uteroglobin/claracell 10-kDa family of proteins: nomenclature committee report. Ann N Y Acad Sci. 2000;923:348–54.PubMedCrossRef Klug J, Beier HM, Bernard A, Chilton BS, Fleming TP, Lehrer RI, Miele L, Pattabiraman N, Singh G. Uteroglobin/claracell 10-kDa family of proteins: nomenclature committee report. Ann N Y Acad Sci. 2000;923:348–54.PubMedCrossRef
8.
Zurück zum Zitat Porter D, Lahti-Domenici J, Torres Arzayus M, Chin L, Polyak K. Expression of high in normal-1(HIN-1) and uteroglobin related protein-1 (UGRP-1) in adult and developing tissue. Mech Dev. 2002;114:201–4.PubMedCrossRef Porter D, Lahti-Domenici J, Torres Arzayus M, Chin L, Polyak K. Expression of high in normal-1(HIN-1) and uteroglobin related protein-1 (UGRP-1) in adult and developing tissue. Mech Dev. 2002;114:201–4.PubMedCrossRef
9.
Zurück zum Zitat Guo MZ, Ren JL, Brock MV, Herman JG, Carraway HE. Promoter methylation of HIN-1 in the progression to esophageal squamous cancer. Epigenetics. 2008;3:336–41.PubMedCrossRef Guo MZ, Ren JL, Brock MV, Herman JG, Carraway HE. Promoter methylation of HIN-1 in the progression to esophageal squamous cancer. Epigenetics. 2008;3:336–41.PubMedCrossRef
10.
Zurück zum Zitat Krop I, Parker MT, Bloushtain-Qimron N, et al. HIN-1, an inhibitor of cell growth, invasion, and AKT activation. Cancer Res. 2005;65:9659–69.PubMedCrossRef Krop I, Parker MT, Bloushtain-Qimron N, et al. HIN-1, an inhibitor of cell growth, invasion, and AKT activation. Cancer Res. 2005;65:9659–69.PubMedCrossRef
11.
Zurück zum Zitat Marchetti A, Barassi F, Martella C, Chella A, Salvatore S, Castrataro A, Mucilli F, Sacco R, Buttitta F. Down regulation of High in Normal-1 (HIN-1) is a frequent event in stage I non-small cell lung cancer and correlates with poor clinical outcome. Clin Cancer Res. 2004;10:1338–43.PubMedCrossRef Marchetti A, Barassi F, Martella C, Chella A, Salvatore S, Castrataro A, Mucilli F, Sacco R, Buttitta F. Down regulation of High in Normal-1 (HIN-1) is a frequent event in stage I non-small cell lung cancer and correlates with poor clinical outcome. Clin Cancer Res. 2004;10:1338–43.PubMedCrossRef
12.
Zurück zum Zitat Krop IE, Sgroi D, Porter DA, Lunetta KL, Vangie RL, Seth P, Kaelin CM, Rhei E, Bosenberg M, Schnitt S, Marks JR, Pagon Z, Belina D, Razumovic J, Polyak K. HIN-1, a putative cytokine highly expressed in normal but not cancerous mammary epithelial cells. PNAS. 2001;98:9796–801.PubMedCrossRef Krop IE, Sgroi D, Porter DA, Lunetta KL, Vangie RL, Seth P, Kaelin CM, Rhei E, Bosenberg M, Schnitt S, Marks JR, Pagon Z, Belina D, Razumovic J, Polyak K. HIN-1, a putative cytokine highly expressed in normal but not cancerous mammary epithelial cells. PNAS. 2001;98:9796–801.PubMedCrossRef
13.
Zurück zum Zitat Baylin SB, Herman JG. DNA hypermethylation in tumorigenesis: epigenetics joins genetics. Trends Genet. 2000;16:168–74.PubMedCrossRef Baylin SB, Herman JG. DNA hypermethylation in tumorigenesis: epigenetics joins genetics. Trends Genet. 2000;16:168–74.PubMedCrossRef
14.
Zurück zum Zitat Herman JG, Graff JR, Myohanen S, Nelkin BD, Baylin SB. Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci USA. 1996;93:9821–6.PubMedCrossRef Herman JG, Graff JR, Myohanen S, Nelkin BD, Baylin SB. Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci USA. 1996;93:9821–6.PubMedCrossRef
15.
Zurück zum Zitat Amaral FR, Bernardes VF, Duarte AP, et al. Quantitative expression analysis of apoptotic/antiapoptotic genes and association with immunolocalization of BAX and BCL-2 in peripheral and central giant cell lesions of the jaws. Tumor Biol. 2011. doi:10.1007/s13277-011-0201-6. Amaral FR, Bernardes VF, Duarte AP, et al. Quantitative expression analysis of apoptotic/antiapoptotic genes and association with immunolocalization of BAX and BCL-2 in peripheral and central giant cell lesions of the jaws. Tumor Biol. 2011. doi:10.​1007/​s13277-011-0201-6.
16.
Zurück zum Zitat Mazumdar J, Hickey MM, Pant DK, Durham AC, Sweet-Cordero A, Vachani A, Jacks T, Chodosh LA, Kissil JL, Simon MC, Keith B. HIF-2a deletion promotes Kras-driven lung tumor development. PNAS. 2010;107:14182–7.PubMedCrossRef Mazumdar J, Hickey MM, Pant DK, Durham AC, Sweet-Cordero A, Vachani A, Jacks T, Chodosh LA, Kissil JL, Simon MC, Keith B. HIF-2a deletion promotes Kras-driven lung tumor development. PNAS. 2010;107:14182–7.PubMedCrossRef
17.
Zurück zum Zitat Coffer PJ, Jin J, Woodgett JR. Protein kinase B (c-AKT): a multifunctional mediator of phosphatidylinositol 3-kinase activation. Biochem J. 1998;335:1–13.PubMed Coffer PJ, Jin J, Woodgett JR. Protein kinase B (c-AKT): a multifunctional mediator of phosphatidylinositol 3-kinase activation. Biochem J. 1998;335:1–13.PubMed
18.
Zurück zum Zitat Odile D, Jett J, LeBeau H, Dy G, Hughes J, Friedman M, Brody AR. Phospho-AKT overexpression in non-small cell lung cancer confers significant stage-independent survival disadvantage. Clin Cancer Res. 2004;10:6865–71. doi:10.1158/1078-0432.CCR-04-0174.CrossRef Odile D, Jett J, LeBeau H, Dy G, Hughes J, Friedman M, Brody AR. Phospho-AKT overexpression in non-small cell lung cancer confers significant stage-independent survival disadvantage. Clin Cancer Res. 2004;10:6865–71. doi:10.​1158/​1078-0432.​CCR-04-0174.CrossRef
19.
Zurück zum Zitat Shah A, Swain WA, Richardson D, Edwards J, Stewart DJ, Richardson CM, Swinson D, Patel D, LouiseJones J, O’Byrne K. Phospho-Akt Expression is associated with a favorable outcome in non -small cell lung cancer. Clin Cancer Res. 2005;11:2930–6.PubMedCrossRef Shah A, Swain WA, Richardson D, Edwards J, Stewart DJ, Richardson CM, Swinson D, Patel D, LouiseJones J, O’Byrne K. Phospho-Akt Expression is associated with a favorable outcome in non -small cell lung cancer. Clin Cancer Res. 2005;11:2930–6.PubMedCrossRef
20.
Zurück zum Zitat Balsara BR, Peil J, Mitsuuchil Y, Page R, Klein-Szanto A, Wang H, Unger M, Testa R. Frequent activation of AKT in non-small cell lung carcinomas and preneoplastic bronchial lesions. Carcinogenesis. 2004;25:2053–9.PubMedCrossRef Balsara BR, Peil J, Mitsuuchil Y, Page R, Klein-Szanto A, Wang H, Unger M, Testa R. Frequent activation of AKT in non-small cell lung carcinomas and preneoplastic bronchial lesions. Carcinogenesis. 2004;25:2053–9.PubMedCrossRef
21.
Zurück zum Zitat Tsurutani J, Fukuoka J, Tsurutani H, Shih JH, Hewitt SM, Travis WD, Jen J, Dennis PA. Evaluation of two phosphorylation sites improves the prognostic significance of AKT activation in non–small-cell lung cancer tumors. J Clin Oncol. 2008;24:306–14.CrossRef Tsurutani J, Fukuoka J, Tsurutani H, Shih JH, Hewitt SM, Travis WD, Jen J, Dennis PA. Evaluation of two phosphorylation sites improves the prognostic significance of AKT activation in non–small-cell lung cancer tumors. J Clin Oncol. 2008;24:306–14.CrossRef
22.
Zurück zum Zitat Danial NN, Korsmeyer SJ. Cell death: critical control points. Cell. 2008;116:205–19.CrossRef Danial NN, Korsmeyer SJ. Cell death: critical control points. Cell. 2008;116:205–19.CrossRef
23.
Zurück zum Zitat Antonsson B. Bax and other pro-apoptotic Bcl-2 family “killer-proteins” and their victim, the mitochondrion. Cell Tissue Res. 2001;306:347–61.PubMedCrossRef Antonsson B. Bax and other pro-apoptotic Bcl-2 family “killer-proteins” and their victim, the mitochondrion. Cell Tissue Res. 2001;306:347–61.PubMedCrossRef
24.
Zurück zum Zitat Cheng EH, Wei MC, Weiler S, Flavell RA, Mak TW, Lindsten T, Korsmeyer SJ. BCL-2, BCL-X(L) sequester BH3 domain-only molecules preventing BAX- and BAK-mediated mitochondrial apoptosis. Mol Cell. 2001;8:705–11.PubMedCrossRef Cheng EH, Wei MC, Weiler S, Flavell RA, Mak TW, Lindsten T, Korsmeyer SJ. BCL-2, BCL-X(L) sequester BH3 domain-only molecules preventing BAX- and BAK-mediated mitochondrial apoptosis. Mol Cell. 2001;8:705–11.PubMedCrossRef
25.
Zurück zum Zitat Desagher S, Osen-Sand A, Nichols A, Eskes R, Montessuit S, Lauper S, Maundrell K, Antonsson B, Martinou JC. Bid-induced conformational change of Bax is responsible for mitochondrial cytochrome c release during apoptosis. J Cell Biol. 1999;144:891–901.PubMedCrossRef Desagher S, Osen-Sand A, Nichols A, Eskes R, Montessuit S, Lauper S, Maundrell K, Antonsson B, Martinou JC. Bid-induced conformational change of Bax is responsible for mitochondrial cytochrome c release during apoptosis. J Cell Biol. 1999;144:891–901.PubMedCrossRef
26.
Zurück zum Zitat Kuwana T, Bouchier-Hayes L, Chipuk JE, Bonzon C, Sullivan BA, Green DR, Newmeyer DD. BH3 domains of BH3-only proteins differentially regulate Bax-mediated mitochondrial membrane permeabilization both directly and indirectly. Mol Cell. 2005;17:525–35.PubMedCrossRef Kuwana T, Bouchier-Hayes L, Chipuk JE, Bonzon C, Sullivan BA, Green DR, Newmeyer DD. BH3 domains of BH3-only proteins differentially regulate Bax-mediated mitochondrial membrane permeabilization both directly and indirectly. Mol Cell. 2005;17:525–35.PubMedCrossRef
27.
Zurück zum Zitat Sasi N, Hwang M, Jaboin J, Csiki I, Lu B. Regulated cell death pathways: new twists in modulation of BCL2 family function. Mol Cancer Ther. 2009;8:1421–9.PubMedCrossRef Sasi N, Hwang M, Jaboin J, Csiki I, Lu B. Regulated cell death pathways: new twists in modulation of BCL2 family function. Mol Cancer Ther. 2009;8:1421–9.PubMedCrossRef
28.
Zurück zum Zitat Certo M, Moore V, Nishino M, Wei G, Korsmeyer S, Armstrong SA, Letai A. Mitochondria primed by death signals determine cellular addiction to antiapoptotic BCL-2 family members. Cancer Cell. 2006;9:351–65.PubMedCrossRef Certo M, Moore V, Nishino M, Wei G, Korsmeyer S, Armstrong SA, Letai A. Mitochondria primed by death signals determine cellular addiction to antiapoptotic BCL-2 family members. Cancer Cell. 2006;9:351–65.PubMedCrossRef
29.
Zurück zum Zitat Parcellier A, Tintignac LA, Zhuravleva E, Hemmings BA. PKB and the mitochondria: AKTing on apoptosis. Cell Signall. 2008;20:21–30.CrossRef Parcellier A, Tintignac LA, Zhuravleva E, Hemmings BA. PKB and the mitochondria: AKTing on apoptosis. Cell Signall. 2008;20:21–30.CrossRef
30.
31.
Zurück zum Zitat Wang H, Mannava S, Grachtchouk V, Zhuang D, Soengas MS, Gudkov AV, Prochownik EV, Nikiforov MA. c-Myc depletion inhibits proliferation of human tumor cells at various stages of the cell cycle Myc-dependent cell cycle regulation in tumor cells. Oncogene. 2008;27:1905–15.PubMedCrossRef Wang H, Mannava S, Grachtchouk V, Zhuang D, Soengas MS, Gudkov AV, Prochownik EV, Nikiforov MA. c-Myc depletion inhibits proliferation of human tumor cells at various stages of the cell cycle Myc-dependent cell cycle regulation in tumor cells. Oncogene. 2008;27:1905–15.PubMedCrossRef
32.
Zurück zum Zitat Kumar R, Blakemorel S, Ellis CE, Petricoin III EF, Pratt D, Macoritto M, Matthews AL, Loureiro JJ, Elliston K. Causal reasoning identifies mechanisms of sensitivity for a novel AKT kinase inhibitor, GSK690693. BMC Genom. 2010;11:419–30.CrossRef Kumar R, Blakemorel S, Ellis CE, Petricoin III EF, Pratt D, Macoritto M, Matthews AL, Loureiro JJ, Elliston K. Causal reasoning identifies mechanisms of sensitivity for a novel AKT kinase inhibitor, GSK690693. BMC Genom. 2010;11:419–30.CrossRef
33.
Zurück zum Zitat Harbour JW, Dean DC. Rb function in cell-cycle regulation and Apoptosis. Nat Cell Biol. 2000;2:65–7.CrossRef Harbour JW, Dean DC. Rb function in cell-cycle regulation and Apoptosis. Nat Cell Biol. 2000;2:65–7.CrossRef
Metadaten
Titel
AKT signaling pathway activated by HIN-1 methylation in non-small cell lung cancer
verfasst von
Yuanzi Yu
Dongtao Yin
Mohammad O. Hoque
Baoping Cao
Yan Jia
Yunsheng Yang
Mingzhou Guo
Publikationsdatum
01.04.2012
Verlag
Springer Netherlands
Erschienen in
Tumor Biology / Ausgabe 2/2012
Print ISSN: 1010-4283
Elektronische ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-011-0266-2

Weitere Artikel der Ausgabe 2/2012

Tumor Biology 2/2012 Zur Ausgabe

Blutdrucksenkung könnte Uterusmyome verhindern

Frauen mit unbehandelter oder neu auftretender Hypertonie haben ein deutlich erhöhtes Risiko für Uterusmyome. Eine Therapie mit Antihypertensiva geht hingegen mit einer verringerten Inzidenz der gutartigen Tumoren einher.

Alphablocker schützt vor Miktionsproblemen nach der Biopsie

16.05.2024 alpha-1-Rezeptorantagonisten Nachrichten

Nach einer Prostatabiopsie treten häufig Probleme beim Wasserlassen auf. Ob sich das durch den periinterventionellen Einsatz von Alphablockern verhindern lässt, haben australische Mediziner im Zuge einer Metaanalyse untersucht.

Antikörper-Wirkstoff-Konjugat hält solide Tumoren in Schach

16.05.2024 Zielgerichtete Therapie Nachrichten

Trastuzumab deruxtecan scheint auch jenseits von Lungenkrebs gut gegen solide Tumoren mit HER2-Mutationen zu wirken. Dafür sprechen die Daten einer offenen Pan-Tumor-Studie.

Mammakarzinom: Senken Statine das krebsbedingte Sterberisiko?

15.05.2024 Mammakarzinom Nachrichten

Frauen mit lokalem oder metastasiertem Brustkrebs, die Statine einnehmen, haben eine niedrigere krebsspezifische Mortalität als Patientinnen, die dies nicht tun, legen neue Daten aus den USA nahe.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.